Home  |  Contact

UniProtKB/Swiss-Prot Q9BZD2: Variant p.Thr449Arg

Equilibrative nucleoside transporter 3
Gene: SLC29A3
Chromosomal location: 10q22.1
Variant information

Variant position:  449
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Threonine (T) to Arginine (R) at position 449 (T449R, p.Thr449Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (T) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Histiocytosis-lymphadenopathy plus syndrome (HLAS) [MIM:602782]: A syndrome characterized by the combination of features from 2 or more of four histiocytic disorders, originally thought to be distinct: Faisalabad histiocytosis (FHC), sinus histiocytosis with massive lymphadenopathy (SHML), H syndrome, and pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome (PHID). FHC features include joint deformities, sensorineural hearing loss, and subsequent development of generalized lymphadenopathy and swellings in the eyelids that contain histiocytes. SHML causes lymph node enlargement in children frequently accompanied by fever, leukocytosis, elevated erythrocyte sedimentation rate, and polyclonal hypergammaglobulinemia. H syndrome is characterized by cutaneous hyperpigmentation and hypertrichosis, hepatosplenomegaly, heart anomalies, and hypogonadism; hearing loss is found in about half of patients. PHID is characterized by predominantly antibody-negative insulin-dependent diabetes mellitus associated with pigmented hypertrichosis and variable occurrence of other features of H syndrome. {ECO:0000269|PubMed:18940313, ECO:0000269|PubMed:19336477, ECO:0000269|PubMed:19889517, ECO:0000269|PubMed:20140240, ECO:0000269|PubMed:20199539, ECO:0000269|PubMed:20399510, ECO:0000269|PubMed:20595384, ECO:0000269|PubMed:20619369, ECO:0000269|PubMed:21888995}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In HLAS; results in reduced nucleoside transport.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  449
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  475
The length of the canonical sequence.

Location on the sequence:   LSTLALLYGPKIVPRELAEA  T GVVMSFYVCLGLTLGSACST
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LSTLALLYGPKIVPRELAEATGVVMSFYVCLGLTLGSACST

Mouse                         LSTLVLIYGPKIVPRELAEATSVVMLFYMSVGLMLGSACAA

Rat                           LSTLVLMYGPKIVPRELAEATSVVMLFYMSLGLMLGSACAA

Bovine                        LSTLALIYGPKIVPRELAEATGVVMTFYMGLGLVLGSACSA

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 475 Equilibrative nucleoside transporter 3
Topological domain 437 – 454 Cytoplasmic


Literature citations

Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability.
Kang N.; Jun A.H.; Bhutia Y.D.; Kannan N.; Unadkat J.D.; Govindarajan R.;
J. Biol. Chem. 285:28343-28352(2010)
Cited for: SUBCELLULAR LOCATION; MUTAGENESIS OF GLY-427; CHARACTERIZATION OF VARIANTS HLAS ARG-116; SER-427; ARG-437 AND ARG-449;

SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway.
Cliffe S.T.; Kramer J.M.; Hussain K.; Robben J.H.; de Jong E.K.; de Brouwer A.P.; Nibbeling E.; Kamsteeg E.J.; Wong M.; Prendiville J.; James C.; Padidela R.; Becknell C.; van Bokhoven H.; Deen P.M.; Hennekam R.C.; Lindeman R.; Schenck A.; Roscioli T.; Buckley M.F.;
Hum. Mol. Genet. 18:2257-2265(2009)
Cited for: VARIANTS HLAS ARG-116; ARG-437 AND ARG-449;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.